Sucampo Pharmaceuticals, Inc. (SCMP) Scheduled to Post Quarterly Earnings on Tuesday
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, August 1st. Analysts expect the company to announce earnings of $0.27 per share for the quarter.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.23 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.28 by $0.05. The business had revenue of $56.30 million for the quarter, compared to analyst estimates of $54.15 million. Sucampo Pharmaceuticals had a return on equity of 43.27% and a net margin of 11.36%. The firm’s revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.21 EPS. On average, analysts expect Sucampo Pharmaceuticals to post $1.01 EPS for the current fiscal year and $1.04 EPS for the next fiscal year.
Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) opened at 11.00 on Tuesday. Sucampo Pharmaceuticals, Inc. has a 52 week low of $9.30 and a 52 week high of $17.55. The firm’s 50-day moving average price is $10.44 and its 200 day moving average price is $10.82. The firm has a market cap of $511.10 million, a P/E ratio of 18.33 and a beta of 1.46.
A number of analysts have recently issued reports on SCMP shares. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Jefferies Group LLC set a $13.00 price target on Sucampo Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, April 20th. Mizuho reiterated a “buy” rating and set a $14.00 price target on shares of Sucampo Pharmaceuticals in a research report on Tuesday, April 4th. Maxim Group reiterated a “buy” rating and set a $21.00 price target on shares of Sucampo Pharmaceuticals in a research report on Thursday, April 13th. Finally, ValuEngine upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $17.00.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.